- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Role of Genetic vs Genomic Testing in Cancer
“When I think about genetic testing, I think about screening,” says David C. Collymore, MD, MBA. In his opinion, genetic testing finds application in “screening large populations of people to see who is susceptible to certain illnesses.”
Genomic testing, on the other hand, has application following diagnosis, according to Dr Collymore. “When an illness has been identified, what treatment can be tailored to improve the outcomes of that individual? One is a screening mindset and the other a treatment mindset,” Dr Collymore explained.
It is necessary, though, to consider the cost-to-benefit ratio for these tests, he advised. “With any screening modality, you want to ensure that the cost of the screening mechanism, over a broader population, makes it an effective [to detect] illnesses in that broader population,” said Dr Collymore.
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
